Coherus BioSciences Appoints Dr. Jill O'Donnell-Tormey to its Board of DirectorsGlobeNewsWire • 05/11/22
Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q1 2022 Earnings Call TranscriptSeeking Alpha • 05/06/22
CORRECTION - Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022GlobeNewsWire • 04/29/22
Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022GlobeNewsWire • 04/29/22
Coherus BioSciences (CHRS) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/28/22
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day EventGlobeNewsWire • 03/29/22
Coherus BioSciences to Highlight New Product Pipeline, Cancer Immunotherapy Development Plans at March 29, 2022 Analyst Day EventGlobeNewsWire • 03/22/22
Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/18/22
Coherus BioSciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 17th, 2022GlobeNewsWire • 02/11/22
Coherus BioSciences Management to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/22
Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development OfficerGlobeNewsWire • 12/17/21